[
  {
    "ts": null,
    "headline": "PracticeQ Partners With Fullscript to Streamline Lab Testing and Improve Patient Care",
    "summary": "SAN DIEGO, January 06, 2026--PracticeQ and Fullscript partner to simplify lab ordering and results management, helping providers deliver faster, more connected care.",
    "url": "https://finnhub.io/api/news?id=bda014ee7d8fb31ac7c0ca691050063dfb024f9d974a423298694e08fd9f566f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767708000,
      "headline": "PracticeQ Partners With Fullscript to Streamline Lab Testing and Improve Patient Care",
      "id": 138000317,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "SAN DIEGO, January 06, 2026--PracticeQ and Fullscript partner to simplify lab ordering and results management, helping providers deliver faster, more connected care.",
      "url": "https://finnhub.io/api/news?id=bda014ee7d8fb31ac7c0ca691050063dfb024f9d974a423298694e08fd9f566f"
    }
  },
  {
    "ts": null,
    "headline": "Data Featuring Haystack MRD® from Quest Diagnostics to be Presented at the 2026 ASCO Gastrointestinal Cancers Symposium",
    "summary": "Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that data will be shared on circulating tumor DNA (ctDNA) minimal residual disease (MRD) testing during two poster presentations at the 2026 ASCO Gastrointestinal Cancers Symposium, being held January 8-10, 2026 in San Francisco, CA., and online. The studies evaluate the use of ctDNA in colorectal cancer using the Haystack MRD® test from Quest Diagnostics.",
    "url": "https://finnhub.io/api/news?id=dd1d468358452dafa84c1df976b17409c7c92b78e4ec7d3a940534fcc0563a2a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767707520,
      "headline": "Data Featuring Haystack MRD® from Quest Diagnostics to be Presented at the 2026 ASCO Gastrointestinal Cancers Symposium",
      "id": 138000740,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that data will be shared on circulating tumor DNA (ctDNA) minimal residual disease (MRD) testing during two poster presentations at the 2026 ASCO Gastrointestinal Cancers Symposium, being held January 8-10, 2026 in San Francisco, CA., and online. The studies evaluate the use of ctDNA in colorectal cancer using the Haystack MRD® test from Quest Diagnostics.",
      "url": "https://finnhub.io/api/news?id=dd1d468358452dafa84c1df976b17409c7c92b78e4ec7d3a940534fcc0563a2a"
    }
  },
  {
    "ts": null,
    "headline": "Hologic's Breast Health Unit Stays In Focus in 2026: What Lies Ahead?",
    "summary": "HOLX's Breast Health unit is back in focus as a proposed Blackstone-TPG deal adds a $76 cash offer and CVR to 2026-27 revenue goals.",
    "url": "https://finnhub.io/api/news?id=d756126254d4def503c36c58c2f489e089275dc43f62df91cbe9e1d1f7d6afa9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767705420,
      "headline": "Hologic's Breast Health Unit Stays In Focus in 2026: What Lies Ahead?",
      "id": 138002325,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "HOLX's Breast Health unit is back in focus as a proposed Blackstone-TPG deal adds a $76 cash offer and CVR to 2026-27 revenue goals.",
      "url": "https://finnhub.io/api/news?id=d756126254d4def503c36c58c2f489e089275dc43f62df91cbe9e1d1f7d6afa9"
    }
  },
  {
    "ts": null,
    "headline": "Should Labcorp Stock Stay in Your Portfolio Right Now?",
    "summary": "LH's growth bets in specialty testing and acquisitions support its outlook, but macro pressures and currency headwinds remain key risks.",
    "url": "https://finnhub.io/api/news?id=9c0bbf2af2c8a80ebbec0e79acc161a92f404bfd04871adc4d22f2f331ac99d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767705120,
      "headline": "Should Labcorp Stock Stay in Your Portfolio Right Now?",
      "id": 138000733,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "LH's growth bets in specialty testing and acquisitions support its outlook, but macro pressures and currency headwinds remain key risks.",
      "url": "https://finnhub.io/api/news?id=9c0bbf2af2c8a80ebbec0e79acc161a92f404bfd04871adc4d22f2f331ac99d4"
    }
  },
  {
    "ts": null,
    "headline": "Assessing Quest Diagnostics (DGX) Valuation After Recent Share Price Momentum And Perceived Undervaluation",
    "summary": "Quest Diagnostics (DGX) has been drawing attention after recent trading left the shares with a negative move over the past month and past 3 months, prompting investors to reassess the company’s fundamentals and valuation. See our latest analysis for Quest Diagnostics. At a share price of US$173.49, Quest Diagnostics has seen short term share price pressure, with a 30 day share price return of 4.94% and a 90 day share price return of 4.09%. This comes even as its 1 year total shareholder...",
    "url": "https://finnhub.io/api/news?id=436a4c4dc9d228a40bbd367b2212a1555d213341dd588698eed98f520b4e70f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767686788,
      "headline": "Assessing Quest Diagnostics (DGX) Valuation After Recent Share Price Momentum And Perceived Undervaluation",
      "id": 137998773,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Quest Diagnostics (DGX) has been drawing attention after recent trading left the shares with a negative move over the past month and past 3 months, prompting investors to reassess the company’s fundamentals and valuation. See our latest analysis for Quest Diagnostics. At a share price of US$173.49, Quest Diagnostics has seen short term share price pressure, with a 30 day share price return of 4.94% and a 90 day share price return of 4.09%. This comes even as its 1 year total shareholder...",
      "url": "https://finnhub.io/api/news?id=436a4c4dc9d228a40bbd367b2212a1555d213341dd588698eed98f520b4e70f6"
    }
  }
]